Table S5. Median survival after 90Y-RE according to baseline LFT (assessed by CTCAE v3 grade) and extent of prior therapy.
| Parameter | CTCAE grade† | Values | Overall cohort (n=606) | SIRT at 2nd-line (n=206) | SIRT at 3rd-line (n=184) | SIRT at ≥4th-line (n=158) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | Median survival (95% CI) | P value | N (%) | Median survival (95% CI) | P value | N (%) | Median Survival (95% CI) | P value | N (%) | Median Survival (95% CI) | P value | ||||||
| Total bilirubin (mg/dL) | 0 | ≤1.3 | 556 (94.0) | 10.4 (9.3–11.9) | <0.001 | 189 (95.0) | 13.2 (10.9–17.2) | <0.001 | 167 (93.0) | 9.1 (7.8–11.2) | 0.937 | 145 (92.0) | 8.7 (6.8–9.5) | <0.001 | |||
| 1 | >1.3–1.95 | 22 (4.0) | 5.1 (2.5–9.0) | 7 (3.0) | 8.5 (0.5–13.1) | 7 (4.0) | 7.4 (1.7–34.8) | 6 (4.0) | 2.7 (1.3–5.1) | ||||||||
| 2 | >1.95–3.9 | 13 (2.0) | 3.8 (1.4–9.9) | 3 (1.5) | 3.2 (1.7–3.8) | 5 (3.0) | 9.9 (1.1–28.4) | 5 (3.0) | 4.1 (0.7–nr) | ||||||||
| 3 | >3.9–13.0 | 1 (0.2) | 0.2 (nr–nr) | 0 | — | 0 | — | 1 (0.6) | 0.2 (nr–nr) | ||||||||
| 4 | >13.0 | 1 (0.2) | 0.7 (nr–nr) | 0 | — | 0 | — | 1 (0.6) | 0.7 (nr–nr) | ||||||||
| Albumin (g/dL) | 0 | ≥3.5 | 392 (66.0) | 13.0 (11.6–13.9) | <0.001 | 133 (67.0) | 16.3 (13.1–18.7) | <0.001 | 126 (71.0) | 10.1 (8.6–12.1) | <0.001 | 94 (59.0) | 9.7 (8.3–13.3) | <0.001 | |||
| 1 | <3.5–3.0 | 127 (21.0) | 7.9 (6.8–9.1) | 45 (23.0) | 9.6 (7.6–16.1) | 35 (20.0) | 7.9 (5.2–11.3) | 41 (26.0) | 6.5 (4.4–8.1) | ||||||||
| 2 | <3.0 – 2.0 | 64 (11.0) | 4.2 (3.6–5.6) | 20 (10.0) | 4.0 (3.0–6.2) | 12 (7.0) | 6.2 (1.4–15.5) | 22 (14.0) | 3.6 (2.3–5.5) | ||||||||
| 3 | <2.0 | 8 (1.0) | 1.5 (0.5–3.0) | 1 (0.5) | 0.5 (nr–nr) | 4 (2.0) | 1.9 (1.1–3.0) | 1 (0.6) | 0.7 (nr–nr) | ||||||||
| ALT (U/L) | 0 | ≤40 | 409 (70.0) | 10.8 (9.0–12.2) | 0.037 | 149 (76) | 13.6 (10.8–17.4) | 0.559 | 120 (67.0) | 9.1 (7.4–11.9) | 0.078 | 94 (61.0) | 7.1 (5.9–9.4) | <0.001 | |||
| 1 | >40–100 | 150 (26.0) | 9.1 (8.2–10.4) | 39 (20.0) | 9.4 (8.1–20.2) | 53 (30.0) | 8.9 (6.1–12.4) | 50 (33.0) | 8.9 (6.5–10.4) | ||||||||
| 2 | >100–200 | 22 (4.0) | 9.5 (4.3–16.3) | 8 (4.0) | 14.7 (2.3–21.4) | 3 (2.0) | 6.5 (1.1–32.4) | 8 (5.0) | 5.0 (1.7–9.5) | ||||||||
| 3 | >200–800 | 2 (0.3) | 5.3 (0.7–9.9) | 0 | — | 1 (0.6) | 9.9 (nr–nr) | 1 (0.7) | 0.7 (nr–nr) | ||||||||
| 4 | >800 | 1 (0.2) | 3.4 (nr–nr) | 0 | — | 1 (0.6) | 3.4 (nr–nr) | 0 | — | ||||||||
| AST (U/L) | 0 | ≤35 | 296 (50.0) | 13.9 (12.2–15.6) | <0.001 | 122 (62.0) | 15.1 (12.2–19.0) | <0.001 | 83 (47) | 11.9 (8.2–15.7) | <0.001 | 62 (40.0) | 13.0 (7.7–15.2) | <0.001 | |||
| 1 | >35–87.5 | 243 (41.0) | 7.9 (6.6–9.0) | 65 (33.0) | 8.5 (6.1–11.1) | 81 (45) | 8.5 (6.5–11.0) | 73 (46.0) | 6.5 (5.1–8.7) | ||||||||
| 2 | >87.5–175 | 42 (7.0) | 4.3 (3.0–9.3) | 8 (4.0) | 15.1 (2.2–21.4) | 10 (6.0) | 3.2 (0.6–5.5) | 20 (13.0) | 4.3 (2.4–7.0) | ||||||||
| 3 | >175–700 | 9 (1.0) | 3.0 (0.2–9.0) | 3 (1.0) | 3.3 (0.9–9.0) | 4 (2.0) | 3.2 (1.1–9.9) | 2 (1.0) | 0.5 (0.2–0.7) | ||||||||
| Alkaline Phospha-tase (U/L) | 0 | ≤126 | 241 (41.0) | 15.7 (13.9–17.7) | <0.001 | 102 (52.0) | 17.4 (13.9–20.0) | <0.001 | 67 (37.0) | 13.9 (9.6–18.6) | <0.001 | 45 (29.0) | 14.0 (9.5–17.7) | <0.001 | |||
| 1 | >126–315 | 252 (43.0) | 8.1 (7.1–9.3) | 71 (36.0) | 9.4 (7.5–12.8) | 86 (48.0) | 7.8 (6.2–9.4) | 73 (46.0) | 7.1 (5.8–9.1) | ||||||||
| 2 | >315–630 | 81 (14.0) | 5.6 (4.5–7.2) | 23 (12.0) | 8.5 (3.3–9.1) | 22 (12.0) | 6.0 (3.0–9.1) | 29 (18.0) | 5.0 (3.9–7.1) | ||||||||
| 3 | >630–2520 | 18 (3.0) | 2.6 (2.0–3.1) | 2 (1.0) | 2.6 (0.9–4.3) | 5 (3.0) | 2.3 (2.0–3.4) | 10 (6.0) | 2.8 (0.7–4.1) | ||||||||
| Creat-inine (mg/dL) | 0 | ≤1.4 | 569 (96.0) | 9.6 (9.0–11.2) | <0.001 | 193 (96.0) | 13.2 (10.6–16.1) | <0.001 | 171 (94.0) | 9.0 (7.8–11.0) | <0.001 | 152 (97.0) | 7.7 (6.4–9.3) | 0.271 | |||
| 1 | >1.4–2.1 | 21 (3.0) | 11.2 (5.4–15.6) | 6 (3.0) | 11.2 (5.7–20.2) | 8 (4.0) | 9.0 (2.9–15.8) | 3 (2.0) | 4.7 (2.0–4.7) | ||||||||
| 2 | >2.1–4.2 | 3 (0.5) | 1.1 (0.8-nr) | 0 | — | 2 (1.0) | 0.9 (0.8–1.1) | 1 (58.0) | nr (nr-nr) | ||||||||
| 3 | >4.2–8.4 | 2 (0.3) | 4.4 (1.7–7.1) | 1 (0.5) | 1.7 (nr-nr) | 0 | — | 0 | — | ||||||||
| 4 | >8.4 | 0 | — | 0 | — | 0 | — | 0 | — | ||||||||
| Hemo-globin (g/dL) | 0 | ≥12.0 | 356 (60.0) | 12.2 (10.6–13.6) | <0.001 | 117 (58.0) | 13.9 (10.9–17.4) | 0.117 | 115 (64.0) | 11.0 (8.5–12.3) | <0.001 | 90 (58.0) | 9.5 (8.2–13.1) | <0.001 | |||
| 1 | <12.0–10.0 | 180 (30.0) | 8.1 (6.5–9.7) | 62 (31.0) | 12.2 (8.5–20.2) | 54 (30.0) | 7.9 (6.2–10.4) | 50 (32.0) | 5.3 (3.9–6.5) | ||||||||
| 2 | <10.0–8.0 | 54 (9%) | 6.0 (4.7–8.6) | 20 (10.0) | 8.9 (3.2–13.6) | 10 (6.0) | 4.4 (1.4–6.0) | 15 (10.0) | 4.7 (3.0–6.3) | ||||||||
| 3 | <8.0–6.5 | 4 (1.0) | 6.9 (4.2–13.6) | 2 (1.0) | 6.9 (4.2–9.6) | 1 (0.6) | 13.6 (nr–nr) | 0 | — | ||||||||
RE, radioembolization; ALT, alanine transaminase; CTCAEs, Common Terminology Criteria Adverse Events; LFT, liver function tests.